AlphaMeld Corporation
Aman Kant is a seasoned professional in the biotechnology and pharmaceuticals sectors, currently serving as Co-founder and Chief Operating Officer at Invea Therapeutics since December 2024. Prior to this role, Aman has held significant positions at InveniAI as Chief Business Officer and Founding Member since April 2017, and at BioXcel Corporation, where contributions spanned from June 2006 to April 2017, including roles such as Vice President, Business Development & Alliances, Director of Business Development & Alliance Management, and Manager of Business Development. Aman Kant holds a Bachelor of Technology in Biotechnology from Jaypee University of Information Technology, obtained between 2002 and 2006.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.